Quest Diagnostics (DGX) Tops Q2 EPS by 30c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $3.12, $0.30 better than the analyst estimate of $2.82. Revenue for the quarter came in at $3.04 billion versus the consensus estimate of $2.97 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.05-$11.25, versus the consensus of $10.77. Quest Diagnostics sees FY2026 revenue of $11.95-12.05 billion, versus the consensus of $11.853 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
• Deutsche Bank Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Hold